Catalyst Clinical Research

Catalyst is a clinical research organisation (CRO)that provides highly customisable solutions to the global biopharmaceutical industry through two established, branded solutions: CatalystOncology and Catalyst Flex. The company provides multi-therapeutic global resourcing and functional services through Catalyst Flex, and full-service oncology CRO offerings through Catalyst Oncology.

With over 800 staff andoffices in the United States and Europe, Catalyst's flexible service model isbuilt from more than a decade of listening to customers, devising customer-centric solutions, and helping customers drive breakthrough clinical studies by leveraging expert teams and innovative technologies.

Company type
Keywords
contract research,oncology
Amy Nguyen
LinkedIn logo VP of Business Development 

Frontier Science (Scotland)

Who we are?

Founded in 2002, Frontier Science (Scotland) Ltd (FSS) is an independent, not-for-profit specialised contract research organisation committed to raising the bar when it comes to designing, running and analysing the results of clinical trials.

We’re a team of 40+ individuals, united in our goal of working on projects that result in public benefit. Our mission is to use a collaborative approach to provide effective, agile solutions and expertise, helping to advance the knowledge of clinical trials, research and statistical science. We have over 20 years of expertise in data management, biostatistics and quality in worldwide clinical trials.

We’re based in the Highlands of Scotland and enjoy an affiliation with Frontier Science organisations in the United States and Greece, as well as worldwide collaborations with customers in industry, academia and health services.

Our Values

 We work with integrity

 We collaborate

 We’re customer-centred

 Continuous learning is at our core

Why work with us?

● Our functional service provision (FSP) approach means that our team will work seamlesslyalongside yours, giving you support in whichever form you need it most

● We’ve been supporting our customers’ clinical trials for over two decades, adapting to

technological advancements along the way

● Our team is highly experienced and committed, providing our clients with support in the design, conduct and analysis of clinical trials

● Our unique position as a not-for-profit partner means we are able to maintain independence and focus on the integrity of the data and analyses we deliver

Biostatistics expertise at your fingertips

Our experienced team of programmers, data analysts and statisticians provide consultancy, regulatory submission and academic research services for studies of all shapes and sizes. Tap into our biostatistics expertise to be sure of accurate, interpretable results.

Biostatistics Services

 Protocol Design Consultancy

 Statistics Analysis Plan (SAP)

 Analyses for Research Projects

 Sample Size Calculations

 Creation of CDSIC datasets

 Reporting

 Independent Data Monitoring Committee (IDMC)

 Regulatory Submissions

 Publishing Results

Data Management - high-quality data delivered on time

Our team of data managers, project managers and database programmers have decades of combined experience. This means you can rely on us to deliver clean, accurate, complete and reliable clinical trial datasets for analysis, every time.

Data Management Services

 Database Design

 Pre-Analysis Database Lock Procedures

 Data Management Documentation

 Data Validation and Integrity

 CDISC Data Extraction

 Case Report Form (CRF) design and annotation

 Data Cleaning

 Reporting

Quality you can count on

We treat quality assurance, quality management systems and technical writing as specialist services alongside our data management and biostatistics expertise. Working with us ensures that every stakeholder in your study can have the utmost confidence in the results.

Quality Services

 Regulatory & Standards Compliance

 Technical Writing

 Clinical Monitoring

 Clinical Quality Management System (QMS) Development

 Trial Master File (TMF) Services

 Pharmacovigilance

Senior Management Team

Our leadership team blends decades of substantial subject matter expertise with business, strategic and people skills. The team is headed up by Dr Darren Gibson, MBA, who joined Frontier Science Scotland in January 2022 with over 20 years of international experience in the health, medical research and innovation sectors.

Company type
Keywords
data management,statistics,clinical trials.
Dr Darren Gibson
LinkedIn logo Executive Director 
Eric Riley
LinkedIn logo Head of Clinical Development and Engagement 
Laura Ross
LinkedIn logo Senior Research Associate 
Vicki Paterson
Senior Research Associate 

Fusion Antibodies


Fusion Antibodies plc is a early discovery partner located in Belfast, which designs, and optimizes therapeutic antibodies for the global healthcare market. Working with early-stage Biotechs, Fusion’s expertise, process frameworks, and development platforms, enables our clients to develop therapeutics within the most challenging modalities and diseases. Fusion guides them through early-stage antibody discovery, in the most efficient and effective way ensuring that the clients can achieve their goals.


The Company was established in 2001 as a spin out from Queen's University Belfast, with an ordinary share offering on AIM on 18th December 2017. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation, and optimisation. These services include antigen expression, antibody production, purification, sequencing, and antibody humanisation. Fusion's proprietary CDRx® and RAMP® platforms provide the clients with antibodies that have a superior probability of reaching the patients.


Since 2012, Fusion Antibodies has successfully developed over 275 antibodies for an international client base. The Company’s growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms, such as OptiMAL®, an unique Mammalian display service offering, that will enable Biotech companies to get to the clinic faster, with the optimal drug candidate.
Company type
Keywords
antibodies
Ryan Tough
LinkedIn logo Distribution Manager 
Richard Buick
LinkedIn logo Chief Scientific Officer 

InSilicoTrials Technologies

Hyper-accelerate drug and medical device development.  Computational models and AI allow to dramatically accelerate the development of new drugs and medical devices, reduce, refine and replace tests on animals and clinical trials, improve the safety of medical products, and significantly cut R&D costs. InSilicoTrials has built an online platform, where Modeling & Simulation is easy to use, regulatory compliant, and cost-effective.

Today, Modeling and Simulation can help companies reduce the very long and expensive development, as well as the subsequent registration/certification processes for new drugs and medical devices up to 50% and greatly accelerate the go-to-market of new products, allowing companies to exploit patents for a longer period. InSilicoTrials solves these problems by selecting and collecting the best models from top researchers around the world and then by integrating them with the solvers in a scalable IT platform, which makes it easier to use validated models without specific computational knowledge, paying only for the used resources.

We cover the entire process with the in silico approach, from preclinical to clinical. Our product portfolio covers a wide range of therapeutical areas and allows our customer to customise the way they want to work with us.

In silico trials allow to get in a few minutes or hours, instead of weeks, outcomes that are more reliable and already compliant with regulatory guidelines.
Company type
Mario Torchia
LinkedIn logo VP sales and marketing 
Luca Emili
LinkedIn logo CEO (founder & CEO) 

Oncimmune

Oncimmune, a global leader in immunodiagnostics and (auto) antibody biomarker profiling & discovery in immuno-oncology, autoimmune and infectious diseases. Through its ImmunoINSIGHTS™ technology platform, the company provides insights to discover and validate novel biomarkers, improve treatment responses and adverse event (irAE) prediction, patient screening and diagnostic accuracy.

Oncimmune is headquartered in the UK with operations in Germany and USA.

Company type
Keywords
oncology
Dr Mike Fisher
LinkedIn logo Vice President, Head of Business Development 

Sygnature Discovery

Sygnature Discovery - enabling success in drug discovery

Sygnature Discovery is a leading independent provider of integrated drug discovery resource and expertise. Since 2011, 35 compounds discovered by Sygnature for our customers have entered pre -clinical development and so far 20 of these have progressed to clinical trials (Phases I, II and III). 

We add considerable value to our clients research projects by providing intellectual input and drug discovery expertise to accelerate target validation, hit identification, hit -to -lead, lead optimisation and preclinical testing. This includes medicinal chemistry, in vitro biology, in vivo pharmacology, computational chemistry, informatics, DMPK, protein sciences and pre -clinical form & formulation. 

Sygnature Discovery is a CRO who's focus is value creation for our clients, through the application of drug discovery know -how and close working relationships. We have built a team of over 600 staff including pharmaceutical industry -experienced research scientists (over 80% PhD qualified) with the ability to collaborate on an equal footing with our clients’ scientists to drive drug discovery projects towards the clinic.

Dr Katie Headland
LinkedIn logo Business Development Manager